1. Home
  2. TONX vs BWAY Comparison

TONX vs BWAY Comparison

Compare TONX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TONX

TON Strategy Company Common Stock

N/A

Current Price

$3.06

Market Cap

248.4M

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$17.27

Market Cap

280.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TONX
BWAY
Founded
N/A
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
248.4M
280.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TONX
BWAY
Price
$3.06
$17.27
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.50
AVG Volume (30 Days)
715.7K
71.4K
Earning Date
11-12-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
213.09
EPS
7.29
0.13
Revenue
$7,760,000.00
$49,094,000.00
Revenue This Year
$526.82
$330.76
Revenue Next Year
$45.45
$22.24
P/E Ratio
$0.42
$53.44
Revenue Growth
3760.70
27.08
52 Week Low
$2.73
$7.84
52 Week High
$29.77
$17.92

Technical Indicators

Market Signals
Indicator
TONX
BWAY
Relative Strength Index (RSI) N/A 60.44
Support Level N/A $16.67
Resistance Level N/A $17.75
Average True Range (ATR) 0.00 0.83
MACD 0.00 0.22
Stochastic Oscillator 0.00 86.93

Price Performance

Historical Comparison
TONX
BWAY

About TONX TON Strategy Company Common Stock

TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: